Impact of the COVID-19 Pandemic on the Antimicrobial Resistance of Klebsiella pneumoniae and Acinetobacter baumannii in an Intensive Care Unit

Authors

  • Gilberto Gambero Gaspar University of São Paulo, Ribeirão Preto Medical School, Department of Social Medicine, Ribeirão Preto, (SP), Brazil https://orcid.org/0000-0002-6804-454X
  • Yasmim Saab Messias University of São Paulo, Ribeirão Preto Medical School, Department of Social Medicine, Ribeirão Preto, (SP), Brazil https://orcid.org/0000-0001-9250-7535
  • Rodrigo de Carvalho Santana University of São Paulo, Ribeirão Preto Medical School, Department of Social Medicine, Ribeirão Preto, (SP), Brazil https://orcid.org/0000-0002-5887-8663

DOI:

https://doi.org/10.11606/issn.2176-7262.rmrp.2026.235692

Keywords:

COVID-19, Bacterial resistance, Healthcare-associated infection

Abstract

Introduction: The COVID-19 pandemic had significant impacts on the prevalence of hospital-acquired infections and the antimicrobial resistance of critical pathogens such as Klebsiella pneumoniae and Acinetobacter baumannii. Objectives: To analyze changes in the sensitivity of these microorganisms and their consequences for hospital infection control. Methods: A retrospective cohort study divided into the Pre-pandemic period (September 1, 2018, to February 28, 2020) and the Pandemic period (March 1, 2020, to August 31, 2021), including adult patients admitted to the Intensive Care Unit. The study analyzed the incidence of Klebsiella pneumoniae and Acinetobacter baumannii, their respective antimicrobial resistance profiles, and the incidence density of Healthcare-Associated Infections (HAIs), comparing the two periods. Results: Among infections, an increase in the incidence density was observed only for Ventilator-Associated Pneumonia. Regarding the bacteria of interest, there was an increase in prevalence for both Klebsiella pneumoniae (8.2% to 21.9% positive cultures/total patients) and Acinetobacter baumannii (7.5% to 21.7% positive cultures/total patients), along with changes in their sensitivity profiles. Conclusion: Based on the results, it can be inferred that the COVID- 19 pandemic had a significant impact on the prevalence and antimicrobial resistance profile of both studied bacteria, along with an increase in reports of Ventilator-Associated Pneumonia.

Downloads

Download data is not yet available.

Author Biographies

  • Gilberto Gambero Gaspar, University of São Paulo, Ribeirão Preto Medical School, Department of Social Medicine, Ribeirão Preto, (SP), Brazil

    Professor Doutor

  • Yasmim Saab Messias, University of São Paulo, Ribeirão Preto Medical School, Department of Social Medicine, Ribeirão Preto, (SP), Brazil

    Médica Assistente

  • Rodrigo de Carvalho Santana, University of São Paulo, Ribeirão Preto Medical School, Department of Social Medicine, Ribeirão Preto, (SP), Brazil

    Professor Doutor

References

1-SAMPAIO, J. L. M.; GALES, A. C. Antimicrobial resistance in Enterobacteriaceae in Brazil: focus on β-lactams and polymyxins. Brazilian Journal of Microbiology, v. 47, p. 31-37, 1 dez.2016.

2-ORGANIZAÇÃO MUNDIAL DA SAÚDE. Member States information session on infection prevention and control (IPC). Overview of the IPC situation Worldwide: highlights of achievement and gaps. Março 2022.

3-ORGANIZAÇÃO MUNDIAL DA SAÚDE. Global report on infection and prevention control. OMS, 2022.

4- VINCENT, J.-L. Nosocomial infections in adult intensive-care units. The Lancet, v. 361, n. 9374, p. 2068-2077, jun. 2003.

5- KOLLEF, M.H. et al. Nosocomial infection. Critical care medicine, v. 49, n. 2, pg. 169-187, 14 jan. 2021.

6- VINCENT, J.-L., et al. International Study of the Prevalence and Outcomes of Infection in Intensive Care Units. JAMA, v. 302, n. 21, p. 2323, 2 dez. 2009.

7- VINCENT, J.-L., et al. Prevalence and outcomes of infections among patients in intensive care units in 2017. JAMA, v. 323, n. 15, p. 1478 - 1487, 21 abr. 2020.

8- SILVA, E. et al. Prevalência e desfechos clínicos de infecções em UTIs brasileiras: subanálise do estudo EPIC II. Revista Brasileira de Terapia Intensiva, v. 24, n. 2, p. 143-150, jun. 2012.

9- BRAGA, I. A. et al. Multi-hospital point prevalence study of healthcare-associated infections in 28 adult intensive care units in Brazil. Journal of Hospital Infection, v. 99, n. 3, p. 318–324, jul. 2018.

10- MAGILL, S. S. et al. Changes in Prevalence of Health Care- Associated Infections in U.S Hospitals. New England Journal of Medicine, v. 379, n. 18, p. 1732-1744, nov. 2018.

11-DESPOTOVIC, A. et al. Hospital acquired infections in the adult intensive care unit- Epidemiology, antimicrobial resistance patterns, and risk factors for acquisition and mortality. American Journal of Infection Control, v. 48, n. 10, p. 1211-1215, out. 2020.

12- Agência Nacional de Vigilância Sanitária. Programa Nacional de Prevenção e Controle de Infecções Relacionadas à Assistência à Saúde (PNPCIRAS) 2021 a 2025. ANVISA. Brasília, 05 mar. 2021.

13- Agência Nacional de Vigilância Sanitária. Critérios diagnósticos de infecções relacionadas à assistência à saúde. 1st ed. Brasília, Brasil: ANVISA; 2013.

14- SCHABERG, D. R.; CULVER, D.H.; GAYNES, R.P. Major trends in the microbial etiology of nosocomial infection. The American Journal of Medicine, v. 91, n. 3, p. S72-S75, set. 1991.

15- WEINSTEIN, R. A.; GAYNES R.; EDWARDS, J. R. Overview of Nosocomial Infections Caused by Gram-Negative Bacilli. Clinical Infectious Diseases, v. 41, n. 6, p. 848-854, 15 set. 2005.

16- VINCENT, J. L. The Prevalence of Nosocomial Infection in Intensive Care Units in Europe.JAMA, v.274, n. 8, p. 634-644, 23 ago. 1995 Agosto, 1995.

17- MAGIORAKOS, A-P. et al. Multidrug-resistant, extensively drug resistant and pandrug-resistant bacteria: an international expert proposal of interim standard definitions of acquired resistance. Clinical Microbiology and Infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases, v. 18, n. 3, p. 268-81, 2012.

18- ANG, H.; SUN, X. Risk factors for multidrug-resistant gram-negative bacteria infection in intensive care units: A meta-analysis. International Journal of Nursing Practice, v. 24, n. 4, p. e12644, 25 mar. 2018.

19- ANDRADE, L.N.; COSTA DARINI, A.L. Beta-lactamase-producing gram-negative bacilli: which bla bla bla is this?. Journal of Infection Control, v. 6, n.1, p. 16-25, jan, 2017.

20- SADER,H. S. et al. Evaluation of the in vitro activity of cefepime compared to other broad-spectrum cephalosporins against clinical isolates from eighteen Brazilian hospitals by using the Etest. Diagnostic Microbiology and Infectious Disease, v. 28, n. 2, p. 87-92, jun. 1997.

21- BUSH, K.; JACOBY, G. A. Updated functional classification of beta-lactamases. Antimicrobial Agents and Chemotherapy, v. 54, n. 3, p. 969-976, 7 dez. 2009.

22- HARRIS, P. N. A.; TMBYAH, P. A.; PATERSON, D. L. β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options? The Lancet Infectious Diseases, v. 15, n. 4, p. 475–485, abr. 2015.

23- JONES, R. N.; MARSHALL, S. A. Antimicrobial activity of cefepime tested against bush group I β-lactamase-producing strains resistant to ceftazidime a multilaboratory national and international clinical isolate study. Diagnostic Microbiology and Infectious Disease, v. 19, n. 1, p. 33-38, maio 1994.

24- MONTEIRO, J. et al. First Report of KPC-2-Producing Klebsiella pneumoniae Strains in Brazil. Antimicrobial Agents and Chemotherapy, v. 53, n. 1, p. 333–334, jan. 2009.

25- NORDMANN, P.; POIREL, L. Emerging carbapenemases in Gram-negative aerobes. Clinical Microbiology and Infection, v. 8, n. 6, p. 321-331, jun. 2002.

26-SOUZA GUSATTI C. et al. First occurrence of bla OXA-58 in Acinetobacter baumannii isolated from clinical sample in Southern Brazil. Brazil Journal and Microbiology. v.43, n.1, p.243-246. Jan.2012.

27- GALES, A. C. et al. Emerging Importance of Multidrug-Resistant Acinetobacter Species and Stenotrophomonas maltophilas Pathogens in Seriously Ill Patients: Geographic Patterns, Epidemiological Features, and Trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clinical Infectious Diseases, v. 32, n. s2, p. S104-S113, 15 maio 2001

28- PAGANO, M. et al. Comparative Analysis of Carbapenem-Resistant Acinetobacter baumannii Sequence Types in Southern Brazil: From the First Outbreak (2007-2008) to the Endemic Period (2013-2014). Microbial Drug Resistance, v.25, n.4, p.538-542, maio 2019

29- MARTINS, A. F. et al. High endemic levels of multidrug-resistant Acinetobacter baumannii among hospitals in southern Brazil. American Journal of Infection Control, v. 40, n.2, p. 108-112, mar. 2012

30- DOI, Y. Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections. Clinical Infectious Diseases, v.69, n.Supplement_7, p. S565-S575, 13 nov. 2019.

31- BORTOLLETI, F. et al. Polymyxin B Resistance in Carbapenem-Resistant Klebsiella pneumoniae, São Paulo, Brazil. Emerging Infectious Diseases, v.22, n.10, p. 1849-1851, out. 2016.

32- LIMA, W. G. et al. Rate of polymyxin resistance among Acinetobacter baumannii recovered from hospitalized patients: a systematic review and meta-analyisis. European Journal of Clinical Microbiology & Infectious Diseases, v. 39, n. 8, p. 1427-1438, 12 jun.2020.

33- GENTELUCI, G. L. et al. Emergence of polymyxin B-resistant Acinetobacter baumannii in hospitals in Rio de Janeiro. Jornal Brasileiro de Patologia e Medicina Laboratorial, 2016.

34- PEREZ, L. R. R. et al. A four-year follow-up survey of antimicrobial resistance among Acinetobacter baumannii complex from inpatients in Southern Brazil. American Journal of Infection Control, v. 49, n.12, p.150-1505, dez.2021

35- ZHU, N. et al. A Novel Coronavirus from Patients with Pneumoniae in China, 2019. New England Journal of Medicine, v.382, n.8, 24 jan. 2020.

36- GUAN, W. et al. Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine, v. 382, n. 18, 28 fev.2020.

37- RUUSKANEN, O. et al. Viral pneumonia. Lancet (London, England), v. 377, n. 9773, p. 1264-75, 2011.

38- RAWSON, T. M. et al. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review to Support COVID-19 Antimicrobial Prescribing. Clinical Infectious Diseases, v. 71, n. 9, 2 maio 2020.

39- LANGFORD, B. J. et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clinical Microbiology and Infection, jan. 2021.

40- GOYAL, P. et al. Clinical Characteristics of Covid-19 IN New York City. New England Journal of Medicine, 17 abr. 2020.

Downloads

Published

2026-11-18

Issue

Section

Original Articles

How to Cite

1.
Gaspar GG, Messias YS, Santana R de C. Impact of the COVID-19 Pandemic on the Antimicrobial Resistance of Klebsiella pneumoniae and Acinetobacter baumannii in an Intensive Care Unit. Medicina (Ribeirão Preto) [Internet]. 2026 Nov. 18 [cited 2026 Nov. 18];59(1):e-235692. Available from: https://revistas.usp.br/rmrp/article/view/235692